MDMA was first made in 1912 as an unintended byproduct of a seek for anticoagulants. Its potential wouldn’t be explored for one more half century till the Nineteen Seventies when the American chemist Alexander Shulgin experimented with the drug and famous its potential to generate emotions of emotional connection. He then launched it to a bunch of therapists who used its results on belief and empathy to bolster their therapeutic effectiveness. Quickly nonetheless, it unfold to the social gathering scene and solely a decade later, in 1985, the DEA made the drug unlawful classifying it as Schedule 1, medicine with no recognized scientific use, which halted additional analysis.
During the last 20 years, analysis into MDMA has reemerged alongside different Schedule 1 medicine resembling LSD and psilocybin (magic mushrooms). These substances have been studied as new remedies for psychological sickness that might be able to counter among the limitations of present medical therapy, together with:
- Partial response: round a 3rd of these with melancholy is not going to enhance after two remedies.
- Long run want for treatment: whereas some individuals can cease, many relapse after stopping treatment. (Rifkin-Zybutz R. & Jauhar S., 2021)
- Uncomfortable side effects of present remedies: Many individuals dislike attribute unintended effects of conventional antidepressants resembling emotional numbness, sexual dysfunction or weight acquire. (Ashton et al., 2005)
- Gradual enchancment: Present remedies usually take at the very least 1-2 weeks to begin to work with maximal results at 4-6 weeks.
Beforehand MDMA has primarily been studied as a therapy for PTSD (Borissova A. & Brooks P., 2022), with trials of quick performing antidepressants primarily restricted to ketamine and psychedelics (DMT, Psilocybin, LSD). This new research (Kvam et al, 2025) is the primary within the trendy period to look at MDMA-assisted remedy as a therapy particularly for individuals with a main prognosis of main depressive dysfunction, moderately than as a secondary final result in PTSD analysis.
MDMA: From psychological well being therapy to social gathering drug and again once more.
Strategies
This trial included 12 members who obtained MDMA in two dosing periods, one month aside, alongside 9 90-minute psychotherapy periods. Individuals had been throughout 18 years outdated and had at the very least reasonably extreme melancholy for between 3 months and a couple of years.
Individuals obtained:
- Session 1: 80 mg MDMA, adopted by an optionally available 40 mg supplemental dose after 90-120 minutes.
- Session 2: 120 mg MDMA, adopted by an optionally available 60 mg supplemental dose after 90-120 minutes.
This was a proof-of-principle research that examined feasibility, not definitive effectiveness and was open-label so each members and experimenters knew what treatment was being given. There was no management group.
Outcomes
This proof-of-principle trial aimed to indicate three issues:
- That this strategy is feasible to do in future research (feasibility).
- There’s preliminary proof of a therapy impact (proof-of-principle efficacy).
- Uncomfortable side effects may be managed and there are not any critical antagonistic occasions (security and tolerability).
Is MDMA-assisted remedy possible?
All scientific trials have particular inclusion and exclusion standards to pick eligible members. Nonetheless, if too many individuals are excluded, recruitment turns into troublesome and the pattern could now not mirror the goal inhabitants.
On this trial, 86 individuals had been screened on the phone, 21 had been purchased in for in-person screening and 15 had been enrolled. Round 20% of individuals had been finally eligible, suggesting feasibility. As a distinction, a current profitable psilocybin trial solely recruited 5% of individuals screened.
15 individuals had been enrolled within the trial, of those 3 left the trial previous to dosing (20%). Causes for dropout included symptom enchancment, issue forming a therapeutic alliance, and lack of social help. This dropout fee could mirror early-stage refinement of recruitment procedures.
Of observe 3/12 sufferers who had been dosed (25%) required extra integration ‘booster’ periods, emphasising the necessity for versatile protocols in future trials and suggesting 9 periods will not be sufficient for a major proportion of people.
Total, the research offered proof it will be doable to run a bigger scale trial.
Is there proof of an MDMA-assisted remedy therapy impact?
Melancholy was measured by the Montgomery-Åsberg Melancholy Score Scale (MADRS). At 2 months post-treatment, members improved on common by 19.3 factors (SD: 8.3), with 75% remission (MADRS ≤12). At 4 months, enchancment remained (imply: 18.4; SD: 11.8) with 8/12 nonetheless in remission.
Total, this can be a massive impact dimension that suggests additional investigation of MDMA-assisted remedy could also be worthwhile.
Did MDMA assisted remedy appear secure?
There have been 46 antagonistic occasions reported, of which 15 had been reasonable and 31 had been delicate. The commonest unintended effects had been headache, elevated suicidal ideation and jaw muscle tightness. No critical antagonistic occasions had been reported (e.g., life threatening occasions, or occasions inflicting hospitalisation or persistent incapacity).
Any improve within the depth of suicidal ideation from baseline was recorded as an antagonistic occasion. 5 of the 12 members had skilled some degree of improve in suicidal ideation after dosing; 3 had been delicate and a couple of reasonable in severity. Of those 4 had been recorded as antagonistic occasions. Most often suicidality will increase had been transient, resolving by follow-up, though in a single participant it endured at a lowered severity. No circumstances of suicidal ideation concerned any intent to behave on the ideas. At a bunch degree, general suicidality scores had been decrease in any respect factors within the research than at baseline.
Total, the therapy was typically properly tolerated. Nonetheless, the sample of fluctuating suicidal ideation highlights the significance of cautious monitoring in future trials, alongside clear procedures for managing adjustments in danger throughout MDMA-assisted remedy.
This small open-label research confirmed that MDMA-assisted remedy was possible, with some proof of early reductions in melancholy and no critical antagonistic occasions, however some transient will increase in suicidal ideation.
Conclusions
The authors concluded that:
The research met the first targets of security and feasibility and offered indications of efficacy for MDMA-AT for MDD. Additional research with a randomised design are required to verify these findings.
This research additionally confirmed that growing depth of suicidal ideas is a typical antagonistic occasion in MDMA-assisted remedy in melancholy which requires extra exploration in future research.
Who may have guessed? The way in which ahead is extra trials.
Strengths and limitations
That is an thrilling new research that gives preliminary proof that MDMA may be secure and efficient in melancholy. Nonetheless, as an early-stage research there are a number of limitations to pay attention to.
Though the results appear very spectacular in dimension; small scale, open label research of medication with highly effective subjective results resembling MDMA usually have very massive results, which then scale back as trials get bigger and extra rigorous. For instance, psilocybin (magic mushrooms) had very massive results in preliminary open label research, which then shriveled in later large-scale trials (Carhart-Harris et al., 2018; Mertens et al., 2026, COMPASS Section 3 Outcomes, 2025). Nonetheless, sustained remission in such a big share of people 4 months after dosing is promising. Due to this fact, these outcomes are an amazing begin however have to be taken as proof of the necessity for extra analysis moderately than definitive proof that MDMA works.
The lack of a management group additionally makes it troublesome to interpret the frequent improve in depth of suicidal ideas. Signs naturally fluctuate in melancholy and from this research alone it’s arduous to know if will increase in suicidality are above this regular degree. For instance, within the placebo arm of a trial testing MDMA for PTSD 41.2% of people had the same improve within the depth of their suicidal ideation through the research, suggesting that this will simply mirror fluctuations in suicidality that happen in psychological sickness (Mitchell et al., 2023).
One other limitation is the affected person group recruited. As a commentary on the article notes, sufferers recruited had a mean of 200 (!) hours of psychotherapy of their previous, which isn’t a mean particular person with melancholy. For instance, a research in Canada discovered that solely 13% of sufferers recognized with melancholy obtained greater than 4 hours of remedy within the yr of prognosis (Puyat et al., 2016). This will imply that this can be a group that’s extra primed than common to answer MDMA and due to this fact would possibly restrict generalisability to the overall inhabitants. Nonetheless, because the authors level out, this additionally implies that this can be a group that’s depressed regardless of all this enter and should spotlight how MDMA can allow breakthroughs for sufferers who aren’t getting higher with current remedies. This could in reality mirror how MDMA was first used within the Nineteen Seventies. Nonetheless future trials might want to see if this protocol works as properly with individuals with much less expertise of psychotherapy.
This research confirmed promising early results and possible supply of MDMA-assisted remedy, however the open-label design, lack of management group, and extremely pre-treated pattern imply the findings want cautious interpretation.
Implications for apply
This early trial lays the muse for additional analysis assessing whether or not there’s a position for MDMA for treating melancholy. Additional analysis is required and there are a number of questions future research must reply earlier than this work may be thought-about in clinic:
1. Does efficacy stay as trials are scaled up and embrace a management arm?
This query shall be extra sophisticated in trials of MDMA as they’re extraordinarily troublesome to blind as a consequence of their attribute unintended effects (Zecharia A., 2025). This makes it unimaginable for the double-blind design to scale back bias in the best way it usually does in scientific trials, as there is no such thing as a blind! This can be a proven fact that the complete psychedelic subject is presently grappling with. Future trials might want to incorporate current methods to scale back this challenge, resembling utilizing third social gathering blinded assessors and lively placebos or pragmatic trials that examine MDMA to current remedies.
2. Is the rise in suicidality clinically important or completely different to placebo?
Whereas there have been no critical antagonistic occasions reported on this trial, 42% of people had a rise in depth of their suicidal ideation. Future trials might want to fastidiously monitor suicidality to check this to fluctuations in suicidality in sufferers receiving a placebo.
3. Who does this therapy work for?
A singular side of psychedelics is their mixture of the psychotherapeutic and psychopharmacological features of therapy. This research occurred in a bunch extraordinarily properly versed in long-term psychological remedy. Future work might want to set up if the identical results may be seen in a inhabitants with much less expertise working psychologically. Moreover, this trial excluded individuals who have been depressed for longer than 2 years. Sufferers with difficult-to-treat melancholy are prone to be the goal group of novel, costly therapies resembling these. Future research also needs to look to discover how MDMA is ready to assist these with long term melancholy signs.
4. How may this therapy be applied in a well being setting?
The described therapy is extraordinarily useful resource intensive. Individuals had 13.5 hours of psychotherapy alongside 2 full day dosing periods for a complete of round 30 hours of contact time. Implementing this protocol in a well being setting can be extraordinarily costly and sure reserved for sufferers who’re extra unwell or personal apply the place individuals pays for therapy. This innately carries with it considerations about fairness of provision if these remedies are finally licenced.
Cautious thought shall be wanted to evaluate how obligatory sure features of remedies are (e.g. do sufferers want two dosings or only one). Along with this, consideration of how remedies shall be built-in into current overstretched well being techniques such because the NHS are key for understanding how they are going to work in apply and guaranteeing that everybody can stand to learn from them.
Total, this research represents an vital first step on the trail to investigating MDMA as a therapy for melancholy. New remedies that work quickly, which are completely different to current therapies, and work for these the place current remedies don’t, are vital. Nonetheless, additional trials and cautious investigation of any will increase in suicidality is required to evaluate if MDMA assisted remedy is a viable therapy for melancholy.
Early MDMA trial exhibits promise for melancholy, however unanswered questions on efficacy, security, scalability and real-world supply imply it stays removed from scientific apply.
Assertion of pursuits
Raphael Rifkin-Zybutz is a PhD scholar and psychiatrist who has labored within the psychedelic subject for 4 years, is working a research involving psilocybin and has labored on a number of psychedelic scientific trials. He’s presently funded by the Medical Analysis Council (MRC).
Editor
Edited by Éimear Foley. AI instruments assisted with language refinement and formatting through the editorial part.
Hyperlinks
Major paper
Tor-Morten Kvam, Ivar W. Goksøyr, Justyna Rog, Inger-Tove Jentoft van de Vooren, Lowan Han Stewart, Ingrid Autran, Mark Berthold-Losleben, Lynn Mørch-Johnsen, René Holst, Ingmar Clausen and Ole A. Andreassen (2025). MDMA-assisted remedy as a therapy for main depressive dysfunction: proof of precept research. British Journal of Psychiatry. https://doi.org/10.1192/bjp.2025.10320
Different References
Rifkin-Zybutz R and Jauhar S. Upkeep or discontinuation of antidepressants for melancholy? Findings from the ANTLER trial, The Psychological Elf, 17 Nov 2021.
Borissova A and Brooks P. How may MDMA-assisted and psilocybin-assisted psychotherapy assist individuals with melancholy and PTSD? The Psychological Elf, 4 Nov 2022.
Zecharia A. Psychedelics and psychological well being: Can the sector ship on its promise? The Psychological Elf, 9 Jul 2025.
Ashton, A.Ok. et al. (2005) ‘Antidepressant-related antagonistic results impacting therapy compliance: Outcomes of a affected person survey’, Present Therapeutic Analysis, Medical and Experimental, 66(2), pp. 96–106. Accessible at: https://doi.org/10.1016/j.curtheres.2005.04.006
Carhart-Harris, R.L. et al. (2018) ‘Psilocybin with psychological help for treatment-resistant melancholy: six-month follow-up’, Psychopharmacology, 235(2), pp. 399–408. Accessible at: https://doi.org/10.1007/s00213-017-4771-x
Mertens, L.J. et al. (2026) ‘Efficacy and Security of Psilocybin in Remedy-Resistant Main Melancholy: The EPISODE Randomized Medical Trial’, JAMA Psychiatry [Preprint]. Accessible at: https://doi.org/10.1001/jamapsychiatry.2026.0132
Mitchell, J.M. et al. (2023) ‘MDMA-assisted remedy for reasonable to extreme PTSD: a randomized, placebo-controlled part 3 trial’, Nature Medication, 29(10), pp. 2473–2480. Accessible at: https://doi.org/10.1038/s41591-023-02565-4
Puyat, J.H. et al. (2016) ‘How Typically Do People with Main Melancholy Obtain Minimally Ample Remedy? A Inhabitants-Based mostly, Knowledge Linkage Examine’, Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie, 61(7), p. 394. Accessible at: https://doi.org/10.1177/0706743716640288
COMPASS Section 3 Outcomes announcement: accessed on 21/04/26 https://ir.compasspathways.com/Information–Occasions-/information/news-details/2026/Compass-Pathways-Efficiently-Achieves-Major-Endpoint-in-Second-Section-3-Trial-Evaluating-COMP360-Psilocybin-for-Remedy-Resistant-Melancholy/default.aspx
